Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Expert Opinion on Investigational Drugs|August 29, 2003
Anti-cancer drug discovery and development summitDavid C Blakey
Cancer Research|March 5, 2003
The first international conference on vascular targeting: meeting overviewPhilip E Thorpe, David J Chaplin, David C Blakey
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatinHisatsugu Goto, Seiji Yano, Yuka Matsumori, et al.
International Journal of Radiation Oncology, Biology, Physics|December 3, 2002
ZD6126: a novel small molecule vascular targeting agentDavid C Blakey, Susan E Ashton, F Russell Westwood, et al.
Cancer Research|July 5, 2002
Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude miceHisatsugu Goto, Seiji Yano, Helong Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor modelsDavid C Blakey, F Russell Westwood, Mike Walker, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767Noel R Monks, David C Blakey, Simon J East, et al.
Neoplasia (New York, N.Y.)|May 14, 2004
Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor modelDominick J O McIntyre, Simon P Robinson, Franklyn A Howe, et al.
Cancer Research|February 21, 2013
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncologyUma Prabhakar, Hiroshi Maeda, Rakesh K Jain, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 9, 2017
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver CancerJon Voutila, Vikash Reebye, Thomas C Roberts, et al.
Pageof 3